צמיחת הכנסות ב-12 חודשים נגררים: Can-Fite (CANF)

Can-Fite BioPharma (CANF) relies on a stable staff of R&D specialists, selectively engaging only foreign coordinators. Optimized raw material supply chains guarantee high margins for its developments. The creation of a therapy ecosystem via adenosine receptors helps treat psoriasis and liver cancer. The historical year-over-year revenue growth trend over the last 12 months demonstrates sales dynamics, where the value settled at 0.00.

Can-Fite BioPharma focuses on developing safe oral medications for the therapy of cancer and liver inflammation. This indicator captures the percentage change in revenue over a rolling year, excluding short-term market fluctuations. The investor analyzes expansion rates to assess the sustainability of the commercialization of developments. Sharp spikes in the relative growth of sales over a 12-month period compared to the previous year may signal rising credit risks. This trend reflects the actual speed of business scaling.